GLG News by SSRI Prescribers (US)

This article is important primarily to those companies and reps who do not pay attention.  Doctors are human and will be most pleased to see those reps who comply with the physician's stated needs.  If the days or hours are limited or an appointment required, the reps need to stay within those...

Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.

MAOI's really work very well in patients in whom tricyclic and newer and safer variations of the theme (blockade of norepinephrine, serotonin, and dopamine uptake) do not.  It is about time that the focus has shifted to a safer version of MAOIs, the selective and reversible novel class of drugs...

Insurance company data is primitive and flawed. Any entity that can manage this data well in the future will be extremely profitable.

Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.

The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...

Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...

An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...

Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...

Cymbalta (Eli Lilly: LLY) solidifies its place in the depression marketplace with this new FDA approval for maintenance treatment.  The incrementaL impact on sales is another matter.